Skip to main content

Advertisement

Table 2 Immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH) results for HER2 protein expression and gene amplification respectively with amplification (in bold) observed in 6/33 (18.2%) mucinous carcinomas.

From: HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy

ID IHC (HER2) HER2/CEP 17 Ratio Patient Outcome IHC/FISH concordance
V1 0 0.8   
V2 3 8.0   
V3 0 1.0   
V4 0 1.1   
V5 3 5+   
V6 3 5.5   
V7 0 1.1   
V8 1 1.9   
V9 0 1.2   
V10 0 6.7   Discordant
V11 0 1.0   
V12 0 0.7   
V13 0 1.0   
V14 0 0.9 Recurrent  
V15 0 1.1   
V16 0 1.1   
V17 0 1.4 Recurrent  
V18 0 1.3 Recurrent  
V19 1 0.8 Recurrent  
V20 2 6.2   
V21 0 1.5 Recurrent  
V22 0 1.2   
V23 0 1.2   
V24 0 1.7 Recurrent  
V25 0 1.1   
V26 0 0.9   
V27 0 1.0 Recurrent  
V28 3 5.1   
V29 1 1.3   
V30 0 1.0   
V31 0 1.2 Recurrent  
V32 0 1.4 Recurrent  
V33 0 1.0 Recurrent